Literature DB >> 16308344

Low plasma protein nitrotyrosine levels distinguish primary Raynaud's phenomenon from scleroderma.

E J Kingdon1, A R Mani, M T Frost, C P Denton, S H Powis, C M Black, K P Moore.   

Abstract

OBJECTIVE: To investigate the hypothesis that increased formation of reactive nitrogen species may contribute to the vascular pathology that develops in patients with connective tissue disease such as scleroderma. PATIENTS AND METHODS: The level of protein-bound nitrotyrosine in plasma was measured by stable isotope dilution gas chromatography/negative ion chemical ionisation mass spectrometry in 11 patients with primary Raynaud's phenomenon, 37 with scleroderma, 13 with chronic renal impairment, and in 23 healthy controls.
RESULTS: Plasma protein-bound nitrotyrosine was markedly decreased in patients with primary Raynaud's phenomenon (mean (SEM) 0.60 (0.06) ng/mg dry protein) compared with patients with scleroderma (1.78 (0.21) ng/mg protein), chronic renal impairment (1.42 (0.17) ng/mg protein) or healthy controls (1.63+/-0.15 ng/mg protein, ANOVA p<0.001).
CONCLUSION: These data suggest that there is decreased nitration of plasma proteins, or increased degradation of nitrated proteins from the circulation of patients with primary but not secondary Raynaud's phenomenon.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16308344      PMCID: PMC1798203          DOI: 10.1136/ard.2005.043562

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  10 in total

1.  Analysis of free and protein-bound nitrotyrosine in human plasma by a gas chromatography/mass spectrometry method that avoids nitration artifacts.

Authors:  M T Frost; B Halliwell; K P Moore
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

2.  Proteolytic degradation of tyrosine nitrated proteins.

Authors:  J M Souza; I Choi; Q Chen; M Weisse; E Daikhin; M Yudkoff; M Obin; J Ara; J Horwitz; H Ischiropoulos
Journal:  Arch Biochem Biophys       Date:  2000-08-15       Impact factor: 4.013

3.  Plasma nitric oxide metabolite in women with primary Raynaud's phenomenon and in healthy subjects.

Authors:  A Ringqvist; J Leppert; U Myrdal; J Ahlner; I Ringqvist; A Wennmalm
Journal:  Clin Physiol       Date:  1997-05

4.  Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin.

Authors:  S A Cotton; A L Herrick; M I Jayson; A J Freemont
Journal:  J Pathol       Date:  1999-10       Impact factor: 7.996

5.  Validity and reliability of three methods used in the diagnosis of Raynaud's phenomenon. The UK Scleroderma Study Group.

Authors:  P Brennan; A Silman; C Black; R Bernstein; J Coppock; P Maddison; T Sheeran; C Stevens; F Wollheim
Journal:  Br J Rheumatol       Date:  1993-05

6.  Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud's syndrome: a randomised trial.

Authors:  A T Tucker; R M Pearson; E D Cooke; N Benjamin
Journal:  Lancet       Date:  1999-11-13       Impact factor: 79.321

7.  Transport of nitrated albumin across continuous vascular endothelium.

Authors:  Dan Predescu; Sanda Predescu; Asrar B Malik
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

8.  Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma.

Authors:  C M Stein; S B Tanner; J A Awad; L J Roberts; J D Morrow
Journal:  Arthritis Rheum       Date:  1996-07

9.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

10.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.